Michael J Sabo is a Lufkin, Texas based male podiatrist who is specialized in Podiatry. Active license number of Michael J Sabo for Podiatry is 0540 in Texas. Michael J Sabo is qualified with a Doctor of Podiatric Medicine (D.P.M.) degree, licensed by the state, and practicing within the scope of that license. He diagnose and treat foot diseases and deformities. He can perform medical, surgical and other operative procedures, prescribe corrective devices and prescribe and administer drugs and physical therapy.
Complete Profile:
Michael J Sabo speciality, credentials, practice address, contact phone number and fax are as below.
Patients can directly walk in or can call on the below given phone number for appointment.
Specialization:
Podiatrist
Credentials:
DPM
Gender:
Male
Practice Address:
300 N John Redditt Dr, Suite 4, Lufkin, Texas, 75904-2606
Phone:
936-632-5252
Fax:
936-632-5284
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details are as mentioned below.
NPI Number:
1508903543
NPI Enumeration Date:
31 Jan, 2007
NPI Last Update On:
08 Jul, 2007
Medical Licenses:
Doctors can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Michael J Sabo are as mentioned below.
License Number
Specialization
State
Status
0540
Podiatry
Texas
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
300 N John Redditt Dr, Suite 4 Lufkin, Texas
Zip:
75904-2606
Phone Number:
936-632-5252
Fax Number:
936-632-5284
Patients can reach Michael J Sabo at 300 N John Redditt Dr, Suite 4, Lufkin, Texas or can call to book an appointment on 936-632-5252. Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 13 May, 2024.